Five-year outcomes of the PROVE-IT randomized controlled trial: Patient-Reported Outcomes of Robotic vs. Laparoscopic Ventral Hernia Repair with Intraperitoneal Mesh - Takeaways - MDSpire

Five-year outcomes of the PROVE-IT randomized controlled trial: Patient-Reported Outcomes of Robotic vs. Laparoscopic Ventral Hernia Repair with Intraperitoneal Mesh

  • By

  • Erika M. Schmidt

  • William C. Bennett

  • Noah X. Tocci

  • Alvaro C. Carvalho

  • Cammy Tang

  • Chao Tu

  • Kimberly S. Miles

  • Luciano Tastaldi

  • Benjamin T. Miller

  • Lucas R. Beffa

  • David M. Krpata

  • Clayton C. Petro

  • Ajita S. Prabhu

  • July 9, 2026

  • 0 min

Share

  • 1

    The PROVE-IT trial compared robotic and laparoscopic approaches to ventral hernia repair using intraperitoneal mesh.

  • 2

    At 1 year, laparoscopic repairs showed lower quality of life compared to robotic repairs despite lower hernia recurrence rates.

  • 3

    The 5-year follow-up aimed to assess long-term outcomes including quality of life, pain intensity, and clinical hernia recurrences.

  • 4

    Patient-reported outcomes were collected using validated surveys, including HerQLes for quality of life and PROMIS 3a for pain.

  • 5

    Clinical hernia recurrence was determined through physical examinations and imaging, with data reviewed by blinded surgeons.

Original Source(s)

Five-year outcomes of the PROVE-IT randomized controlled trial: Patient-Reported Outcomes of Robotic vs. Laparoscopic Ventral Hernia Repair with Intraperitoneal Mesh

  • by Erika M. Schmidt, William C. Bennett, Noah X. Tocci, Alvaro C. Carvalho, Cammy Tang, Chao Tu, Kimberly S. Miles, Luciano Tastaldi, Benjamin T. Miller, Lucas R. Beffa, David M. Krpata, Clayton C. Petro, Ajita S. Prabhu

  • July 9, 2026

Related Content

The clinical value of pediatric laparoscopic surgery using umbilical S-shaped incision

Can Belzutifan Improve Adjuvant Therapy?

The phase 3 LITESPARK-022 trial compared adjuvant pembrolizumab plus belzutifan with pembrolizumab plus placebo following resection of clear-cell renal-cell carcinoma.

Efficacy and safety of neoadjuvant chemotherapy with immunotherapy versus chemotherapy alone in esophageal squamous cell carcinoma: a meta-analysis based on randomized controlled trials